Teriparatide

See source wording

under the skin · daily · for 12 months

Sequential Therapies After Osteoanabolic TreatmentNot stated · NCT06164795

“Abaloparatide Injection (80 mcg).”

See source wording

by mouth · weekly · for 12 months

Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With TeriparatidePHASE2 · NCT02195895

“Weekly oral alendronate 70 mg for 12 months.”

See source wording

under the skin · daily

Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa).PHASE3 · NCT04750460

“Subcutaneous injections of study drug will be assigned immediately after parathyroidectomy (20 mcg), on the 1st (20 mcg) and 2nd (10 mcg) postoperative day..”

See source wording

by mouth · for 3 years

Effects of Teriparatide in the Treatment of Postmenopausal Women With OsteoporosisPHASE3 · NCT00670501

“Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement.”

20 mcg

daily · for 4 weeks

Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?PHASE4 · NCT02090244

“Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks.”

20 mcg

under the skin · daily

Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs PlaceboPHASE4 · NCT01734824

“daily subcutaneous injection of teriparatide 20µg for three months.”

20 mcg

under the skin · daily · for 12 weeks

Teriparatide for Fracture Repair in HumansPHASE3 · NCT02091492

“Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks.”

See source wording

under the skin · once a week

To Evaluate the Efficacy and Safety of SAL056 for Postmenopausal Women With Osteoporosis at High Fracture RiskPHASE3 · NCT07028320

“SAL056 (56.5μg).”

20 mcg

daily · for 12-24 months

Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur FracturesPHASE3 · NCT01896011

“Teriparatide 20 mcg.”

20 mcg

under the skin · daily · for 24 weeks

A Comparison of PF708 and Forteo in Osteoporosis PatientsPHASE3 · NCT03002428

“PF708 20 mcg once-daily subcutaneous injection for 24 weeks.”

See source wording

under the skin · daily

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic AcidPHASE4 · NCT03735537

“Any brand or preparation may be used to deliver the required dose of 5mg.”

5 mg

into a vein · daily

The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis ImperfectaPHASE2 · NCT01679080

“yearly intravenous infusion of 5mg active zoledronic acid in 3 yr.”

See source wording

under the skin · every 12 hours · for 7 days

Teriparatide (Forteo) in the Treatment of Patients With Postoperative HypocalcemiaPHASE2 · NCT00623974

“Teriparatide 20 mcg.”

20 mcg

daily · for 12 months

12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)PHASE2 · NCT02025179

“Teriparatide 20 ug daily Sub-Q over 12 months.”

See source wording

Teriparatide on Maxillary Sinus Floor OsseointegrationPHASE4 · NCT06061354

“mixture of 20μg of teriparatide, 0.64ml of saline solution with 1g of Bio -Oss® or 1g of Bio-Oss® will be mixed with 0.72ml of saline solution..”

20 mg

daily

Fracture Recovery for Returning to Duty (Teriparatide STRONG)PHASE4 · NCT04589819

“Subjects in the teriparatide arm will receive a 20mg dose of the medication daily via self-injection..”

1000 mg/day

by mouth · once a week

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip FracturePHASE4 · NCT00887354

“Approximately 500 to 1000 mg/day administered orally throughout study..”

See source wording

under the skin · once a day

Comparative Study for Incidence of Proximal Junctional Kyphosis Between Parathyroid Hormone and Denosumab Following Adult Spinal Deformity Surgery : A Prospective, Randomized Controlled TrialPHASE4 · NCT04241211

“Patients were administered 20mcg of TP (Forsteo) subcutaneously once a day from the day between before 3months to after 3months about surgery..”

1 mg

under the skin

The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral DensityPHASE4 · NCT00446589

“iv 1mg ibandronate monthly for one year.”

20 mcg

under the skin · once daily · for 6 months

Efficacy of WJ-derived Mesenchymal Stem Cells in Combination With Parathyroid Hormone for Vertebral Compression FracturePHASE2 · NCT05018637

“Other: subcutaneous injection of 20 µg teriparatide once daily for 6 months, followed by oral administration of anti-resorptive drug for 6 months.”

20 mcg

under the skin · for 18 months

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With TeriparatidePHASE4 · NCT00557310

“20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months.”

20 mcg

daily

Preoperative Teriparatide Use on Insertional Torque of Pedicle Screws for Lumbar Fusion SurgeryNA · NCT03770338

“20ug dosage daily injection, 1-month preoperative.”

20 mcg

under the skin · once daily · for 12 weeks

Chronotherapeutic Optimization of Teriparatide Administration in Postmenopausal OsteoporosisNA · NCT06951776

“Eligible participants will be randomly assigned (1:1) to either subcutaneous injection of 20 μg teriparatide at 08:00 a.m.”

See source wording

by mouth · every 6 hours · for 6 months

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With OsteoporosisPHASE4 · NCT01753856

“Tetracycline (TET): Beginning 22 days prior to the biopsy procedure: Days 1, 2, 3 and 16, 17, 18: 250 mg TET will be taken orally every 6 hours; Days 4 through 15: TET will not be administered.”

100 IU/day

under the skin

Comparison Medications in the Treatment of Postmenopausal Women With OsteoporosisPHASE3 · NCT00542984

“salmon calcitonin 100 IU/day subcutaneous.”

See source wording

under the skin · once a month · for 12 months

Romosozumab/Denosumab Study for Premenopausal IOPPHASE2 · NCT04800367

“2 syringes of 105 MG/1.17 mL subcutaneous solution injected one after the other, once a month from study baseline through 11 month visit.”

20 mcg

under the skin

Pharmacokinetic and PHarmacodynamic Analysis and Evaluation of Teriparatide (PTH 1-34) Between SexesPHASE3 · NCT04921124

“Teriparatide, 20 µg Subcutaneous (S/C) per day.”

See source wording

under the skin · once a month · for 12 months

An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal WomenPHASE3 · NCT01796301

“Participants received 210 mg romosozumab administered by subcutaneous injection once a month for 12 months..”

See source wording

under the skin · once a day · for 12 months

µMRI of Therapeutic Intervention in Postmenopausal OsteoporosisPHASE4 · NCT01153425

“20 µg of Teriparatide will be self-injected subcutaneously once a day for 12 months and an MRI at 3T ('Virtual Bone Biopsy') will be performed at 0 and 12 months..”

20 mcg

under the skin · daily · for 24 weeks

Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMDPHASE2 · NCT00624481

“20ug subcutaneous injection daily for 24 weeks.”

20 mcg

under the skin · daily

Study to Evaluate Effect of Intranasal Teriparatide on Serum P1NP, a Biomarker of Bone Formation, in Postmenopausal Women With Low Bone MassPHASE2 · NCT01604057

“20 mcg subcutaneous daily.”

See source wording

dogs · weekly · for 20 weeks

Synergistic effects of intermittent parathyroid hormone (1-34) and masticatory force for alveolar bone remodeling in the maxilla of dogs.Journal of stomatology, oral and maxillofacial surgery · 2026

“Methods In this exploratory pilot study, three male mongrel dogs were each assigned to a single dose group (n = 1 per group) and injected weekly for 20 weeks with vehicle (CON), 1.6 μg/kg PTH (PTH1.6), or 3.2 μg/kg PTH (PTH3.2).”